Correspondence 0001193125-24-217279 from Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc
Date: Sept. 11, 2024 · CIK: 0001541157 · Accession: 0001193125-24-217279
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281995
Letter
Akari Therapeutics, Plc
22 Boston Wharf Road, FL 7
Boston, MA 02210
September 11, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-7553
Attention: Doris Stacey Gama
Re: Akari Therapeutics, Plc
Registration Statement on Form S-3
Filed September 6, 2024 (File No. 333-281995)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, Plc (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-281995) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:05 P.M., Eastern Time, on September 13, 2024, or as soon thereafter as is practicable.
Please contact Justin S. Platt, Esq. of Goodwin Procter LLP, counsel to the Company, at (212) 459-7340 to provide notice of effectiveness, or if you have any questions or comments concerning this request.
[Remainder of the page intentionally left blank]
Very truly yours,
AKARI THERAPEUTICS, PLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP Akari Therapeutics, Plc 22 Boston Wharf Road, FL 7 Boston, MA 02210 September 11, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-7553 Attention: Doris Stacey Gama Re: Akari Therapeutics, Plc Registration Statement on Form S-3 Filed September 6, 2024 (File No. 333-281995) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, Plc (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-281995) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:05 P.M., Eastern Time, on September 13, 2024, or as soon thereafter as is practicable. Please contact Justin S. Platt, Esq. of Goodwin Procter LLP, counsel to the Company, at (212) 459-7340 to provide notice of effectiveness, or if you have any questions or comments concerning this request. [Remainder of the page intentionally left blank] Very truly yours, AKARI THERAPEUTICS, PLC By: /s/ Samir R. Patel, M.D. Name: Samir R. Patel, M.D. Title: Interim President and Chief Executive Officer